Celldex Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.5 | $7.0 | $6.9 | $2.4 | $4.7 |
| Operating income | -$287.4 | -$195.1 | -$154.5 | -$115.2 | -$71.2 |
| Net income | -$258.8 | -$157.9 | -$141.4 | -$112.3 | -$70.5 |
| Cash Flow Statement | |||||
| Free cash flow | -$213.7 | -$159.7 | -$109.1 | -$105.6 | -$62.2 |
Shares outstanding 78.5M · Free float 92.4%
Annual filing data through FY ended December 31, 2025; float as of September 20, 2026.